Introduction {#S1}
============

Major depressive disorder (MDD) is a major health concern associated with brain and immune system abnormalities. It plays a significant role in the global burden of diseases by affecting people in all communities across the world. According to recent epidemiological surveys, it has been estimated that by 2020, MDD will be the 2nd leading diseases worldwide ([@B31]; [@B32]). The central nervous system (CNS) responds to the pathogen and several cellulars stress processes through neuro-inflammation, which can induce molecular dysregulation and can be a critical control point for the development of depression ([@B74]; [@B81]). It has been reported that failure in adaptation to psychological or physical stress can lead to depression which is mediated by an inflammatory response and cytokines ([@B87]; [@B28]). Several lines of evidence from both clinical and experimental data have strongly proposed that internal and external stress significantly affects the expression of depressive symptoms and their persistence is associated with immunological abnormalities ([@B87]; [@B24]; [@B28]). An elevated level of microglia activation has been reported in individuals with depression who commit suicide, suggesting that neuroinflammation contributes a significant role in the pathogenesis of depression ([@B8]). The immune system could also affect the CNS through cytokines, which not merely participate in cell-to-cell communication but also affect the regulatory and processing mechanism of neurochemicals and neuroendocrine that are the key regulator of physiological and behavioral alterations ([@B28]). Activated peripheral immune system increase cytokines production and flow to CNS, where they induce the activation of astrocytes and microglia, which in turn elevates cytokines production ([@B55]; [@B75]). Moreover, the crosstalk between microglia and astrocytes under stress condition involve in neuroinflammation that leads to dysfunction in the neurotrophic system, which may contribute to the pathogenesis of MDD ([@B75]).

Dysregulation in the redox-sensitive signalings has been shown to play a major role in an immune imbalance that leads to depression ([@B48]). Enhanced reactive oxygen species (ROS) overwhelms the antioxidant defense system that leads to oxidative stress, which in turn participates in the pathogenesis of numerous diseases including neurological abnormalities ([@B3]; [@B67]; [@B77]). Accumulative results support the increased expression of pro-inflammatory cytokines that occurred via the activation of transcription factor NF-κB under stress condition ([@B56]; [@B29]; [@B28]), as demonstrated by NF-κB activation by inflammatory cytokines and lipopolysaccharide (LPS; [@B66]; [@B29]). Apart from its pro-inflammatory function, NF-κB is also involved in the oxidative/anti-oxidative stress regulation, which in turn affect cytokine production ([@B37]; [@B30]; [@B42]; [@B13]). Interestingly, NF-κB regulates Nrf2 transcription and activity, which not only elevates antioxidant capacity but also induces the expression of a neuroprotective protein, such as brain-derived neurotrophic factors (BDNF), anti-inflammatory protein Hemoxygenase-1 (HO-1), and anti-inflammatory cytokines ([@B71]; [@B12]), indicating the intricate interplay between neuroinflammation and oxidative stress systems. Further, Sirt1 regulation has been also currently reported in mood disorders both in the animal models as well as humans ([@B34]; [@B27]; [@B44]). Numerous studies have reported that Sirt1 can reduce inflammation as well as oxidative stress ([@B2]; [@B68]; [@B27]), therefore, a stress inducer like LPS may suppress Sirt1 expression ([@B25]; [@B17]; [@B4]; [@B73]).

Numerous studies have reported the beneficial effects of exogenous melatonin on the brain, which might include the activation of melatonin membrane receptors (MMRs). Luzindole (*N*-acetyl-2-benzyltryptamine) is a well-known high selective MMR antagonist and is widely employed to study the action of melatonin on the signaling pathways and the associated neuroendocrine and functional responses ([@B60]; [@B15]).

Melatonin (N-acetyl-5-methoxytryptamine) is the main neurohormone of pineal glands. It regulates the major physiological process via its receptors (MT1, MT2), which are specific G-protein coupled receptors to regulate downstream molecules phospholipase C (PLC), guanylyl cyclase (GC), adenylyl cyclase (AC), cyclic guanosine monophosphate (cGMP), and as well as calcium and potassium channels ([@B57]; [@B18]; [@B79]). MT1 and MT2 receptors are expressed in the CNS including the hippocampus, suprachiasmatic nucleus (SCN), and tegmental areas together as well as separately ([@B23]). Melatonin is a key immunomodulatory and neuroprotective via its antioxidative and anti-inflammatory mechanisms, presumably by encountering the free radicals ([@B23]; [@B18]; [@B9]; [@B19]). Previous studies reported that the free radical scavenging actions of melatonin are receptor-independent ([@B62]; [@B92]; [@B46]; [@B95]), while it also regulates antioxidant enzymes including superoxide dismutase and catalase through receptor-dependent mechanisms ([@B64]; [@B65]; [@B63]; [@B94]). Herein we tried to explore the molecular mechanisms of melatonin involved in stress-induced neuroinflammation, an essential strategy against MDD.

Materials and Methods {#S2}
=====================

Animal and Drug Treatment {#S2.SS1}
-------------------------

Adult C57BL/6J male mice weighing 25--30 *g* (7--8 weeks) were purchased from Guangdong medical laboratory animal center, China. The experimental animals were housed at Laboratory Animal Research Center, Peking University Shenzhen Graduate School, under 12 h light/12 h dark cycle at 18--22°C, and had free access to diet and tap water throughout the study. The experimental procedures were set in such a way to minimize mice suffering. All experimental procedures were carried out according to the protocols approved by the Institutional Animal Care and Use Committee of Peking University Shenzhen Graduate School. The experimental animals were divided into seven groups (each group *n* = 6): normal saline-treated, LPS (1 mg/kg/day) treated, LPS + Melatonin (10 mg/kg/day) treated, LPS + Fluoxetine (10 mg/kg/day), Melatonin (10 mg/kg/day) treated, LPS + Melatonin + luzindole (5 mg/kg/day) treated, and LPS + luzindole treated. Drugs (Melatonin Fluoxetine, and luzindole) were treated intraperitoneally (12 pm to 2 pm) 1 h before LPS treatment daily for 5 days. Both drugs melatonin and luzinolde were dissolved in 5% DMSO and were administrated according to the previously described protocol ([@B54]; [@B98]; [@B84]). The drug treatment schedule has been shown in [Figure 1A](#F1){ref-type="fig"}. After 24 h of last LPS injection, mice were sacrificed. Serum and brain tissues were collected and stored at freezing temperature (−80°C) until further analysis.

![Drug treatment schedule and LPS effect on body weights **(A)** Drugs treatment schedule. Melatonin/Fluoxetine/Luzindole was administrated (i.p) 1 h before the LPS treatment for 5 days. **(B)** Relative body weights differences. (*n* = 6 per group). Data are expressed as mean ± SEM, andresults were analyzed using one-way ANOVA followed by *post-hoc* analysis. *p* \< 0.05 wasconsidered statistically significant. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001.](fnmol-13-00096-g001){#F1}

Open Field Test {#S2.SS2}
---------------

Open field test (OFT) was performed according to the previously developed protocols ([@B93]). Briefly, mice were adapted to the experimental room for 1 h and were placed in the chamber of 45 × 45 × 30 cm. A total of 15 min video was recorded to observed the mice locomotor activity. The total distance covered by mice was measured, analyzed, and expressed in meters.

Sucrose Preference Test {#S2.SS3}
-----------------------

A sucrose preference test (SPT) was performed ([@B11]) while using a two-bottle free-choice paradigm. Mice were habituated with a 1% sucrose solution for 3 days and finally grouped randomly. To assess THE individual sucrose intake, mice were deprived of water and food for 24 h on the 3 days of drug administration. On the next day, each mouse had free access to two bottles containing sucrose and water, respectively. The position of water and sucrose-containing bottles were changed after 12 h. Finally, the volume of consumed water and sucrose solution were recorded and calculated by the following formula:
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Forced Swimming Test {#S2.SS4}
--------------------

The forced swimming test (FST) was performed according to previously developed protocols ([@B71]). The experimental animals were trained for swimming and pre-experiment FST was performed to select healthy and normal mice. To perform the FST, the animals were placed in a Plexiglas cylinder (height: 70 cm, diameter: 30 cm) filled with water over the 30 cm level at a temperature of 23 ± 1°C. The video was taped for 6 min and the last 5 min were blindly analyzed. Mice were considered immobile when they remained floating motionless in the water and just making a move to keep their nose above the water surface. The horizontal movement of the animals throughout the cylinder was defined as swimming while vertical movement against the wall of the cylinder was defined as climbing. EthoVision XT was used to record the video and analysis.

Tail Suspension Test {#S2.SS5}
--------------------

Tail suspension test (TST) was performed according to the previously described protocol ([@B78]; [@B93]). The experimental animals were suspended upside down by tails 40 cm above the floor by adhesive tape placed 1 cm from the tail tip. The immobility time was scored for the first 2 min of a total 4 min video. EthoVision XT software was used for TST video recording and analysis.

Serum ROS Level Measurement {#S2.SS6}
---------------------------

Reactive oxygen species were analyzed by a previously developed method ([@B20]; [@B6]). Briefly, hydrogen peroxide/serum (5 μL/well) was added to 140 μL of 0.1 M sodium acetate buffer (pH 4.8) in a 96-well microtiter plate. A mixture (100 μL) which was prepared from reagent R1 (100 μg/ml DEPPD in 0.1 M Sodium acetate buffer, pH 4.8) and R2 (4.37 μM ferrous sulfate in 0.1 M sodium acetate buffer) at a ratio of 1:25 was added in each well. Then, after free incubation of 1 min, absorbance at 505 nm was measured using a plate reader (Envision 2104, PerkinElmer).

TBARs Assay {#S2.SS7}
-----------

Thiobarbituric acid reactive substance (TBARs) level was estimated ([@B5]) to determine the damage to lipids caused by ROS in various experimental groups. Briefly, 0.1 ml of sample (Hippocampal tissue immunomodulatory), 0.1 ml FeSO4, 0.1 ml Tris--HCl, 0.6 ml distilled water, and 0.1 ml Ascorbic Acid were incubated at 37°C in a test tube for 15 min and then 1 ml TCA and 2 ml TBA were added. These plugged test tubes were incubated for 15 min at 100°C followed by centrifugation at 3000 rpm for 10 min. The supernatant O.D. was determined at 532 nm and the following formula was applied to estimate TBARs as nM/mg protein: TBARs (nM/mg protein) = O.D × Total volume × Sample volume × 1.56 × 105 × mg protein/ml (1.56 × 105 = Molar Extinction Coefficient).

ELISA {#S2.SS8}
-----

The frozen hippocampal tissue was lysed with RIPA buffer and homogenized on ice. Supernatants were collected after centrifugation at 10,000 *g* for 10 min and stored at freezing temperature for further analysis. The expression of cytokines was quantified using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's protocols (IL-6 Cat NO: RK00008, IL-1β Cat NO: RK00006, and TNFα Cat NO: RK00027, ABclonal Biotechnology Co., Ltd, Wuhan, Hubei Province, China). Briefly, after washing the wells of 96-well plate, 100 μL standard/sample (sample serum/hippocampus tissues) was added and incubated for 2 h at 37°C. The plate was then washed and a biotin-conjugated antibody (1:30) was added to each well. The plate was incubated for 1 h at 37°C. streptavidin-HRP was added for 30 min at 37°C. Finally, the reaction was stopped and the optical density was measured accordingly.

Immunofluorescence {#S2.SS9}
------------------

Immunofluorescence staining was performed according to previously reported protocols ([@B73]). Briefly, brain tissue sections (20 μm thick) were washed with PBS for 15 min (5 min × 3). After washing, the sections were treated with blocking buffer (10% Goat serum in 0.3% Triton X--100 in PBS) for 1 h at room temperature. After blocking the tissue was treated with primary antibodies with a dilution ratio of 1:500 μL (Iba1, GFAP) for overnight at 4°C. Next day secondary antibodies 1:400 μL (Alexa Flour secondary antibodies, ThermoFisher, Waltham, MA, United States) were applied at room temperature for 1 h. The sections were washed with PBS for 5 min three times. After washing, sections were transferred to slides, and glass coverslips were mounted using the mounting medium. The images were taken under inverted fluorescence microscope IX73 Olympus. ImageJ software was used to quantify the relatively integrated density of GFAP and Iba-1.

Western Blotting {#S2.SS10}
----------------

To extract the protein hippocampal tissue was lysed with RIPA buffer and homogenized on ice. Supernatants were collected after centrifugation (10,000 rpm for 10 min). The immunoblotting was also performed according to the developed protocols. Briefly, denatured samples (boiled at 100°C for 5 min) were separated on SDS-PAGE and then transferred to the nitrocellulose membrane. The membrane was blocked in with non-fat milk in TBST (Tris--buffered saline, 0.1% Tween 20), then incubated in primary antibody (1:1000 dilution used for Nrf2, *p*-NFkB, NFkB, *p*-GSK-3b, GSK-3b, Ho-1, GAPDH, Tubulin, 1:2000 dilution was used for *p*-Akt, and Akt) overnight at 4°C. The primary antibodies were diluted according to the company provided protocol. The next day membrane was treated with a secondary antibody (1:1000) for 1 hr at 4°C. For detection, the ECL Super signal chemiluminescence kit was used according to the manufacturer's protocol. Blots were developed using Chemidoc mp Bio-red, Hercules, CA, United States. The densitometry analysis of the bands was performed using image lab software.

List of Antibodies Used {#S2.SS11}
-----------------------

Anti-Nrf2 (cell signaling, Lot: 12721), Anti-p-NFkB (Cell signaling, Lot: 3033), Anti-NF-κB (Cell signaling, Lot: 8242), Anti-p-GSK3b (Santa Cruz, Lot: sc-11757), Anti-GSK3B (Santa Cruz Lot: sc-9166), Anti-p-Akt (Cell signaling, Lot: 4060), Anti-Akt (Cell signaling, Lot: 4691), Anti-HO-1 (Cell signaling, Lot: 70081), Anti-Sirt1 (Cell signaling, Lot: 8469), Anti-GAPDH (Cell signaling, Lot:5174), and Anti-Tubulin (Santa Cruz, Lot: sc-8035).

Statistical Analysis {#S2.SS12}
--------------------

Western blot bands and morphological data were analyzed using ImageJ software (Image J 1.30) and analyzed by SPSS Statistics 21 (IBM, United States) and GraphPad Prism 5 software. Data were presented as mean ± SEM. One way/two way ANOVA followed by *post hoc* Tukey/Bonferroni Multiple Comparison tests were performed to compare different groups, using the graph-pad prism-5 software. *P* \< 0.05 was regarded as significant. (^∗^): *p* \< 0.05, (^∗∗^): *p* \< 0.01), and (^∗∗∗^): *p* \< 0.001.

Results {#S3}
=======

Melatonin Reduced LPS Induced Depressive-Like Behavior {#S3.SS1}
------------------------------------------------------

Previous studies have reported that LPS can induce depressive-like behaviors ([@B58]; [@B7]). Herein, LPS induced depressive-like behaviors were measured at 24 h post LPS (last) injection by assessing changes in the body weight ([Figure 1B](#F1){ref-type="fig"}), locomotor activity ([Figure 2A](#F2){ref-type="fig"}), and immobility duration. LPS-treated mice showed sucrose preference less than 65% for a 1% sucrose solution ([Figure 2B](#F2){ref-type="fig"}) and increased immobility duration ([Figures 2C,D](#F2){ref-type="fig"}), however, this effect was blocked by pre-melatonin treatment. Moreover, it was interesting in the report that luzindole (melatonin receptor inhibitor) treatment significantly abolished melatonin protective effects, suggesting that endogenous melatonin can block the onset of LPS induced depressive-like behaviors. Fluoxetine was used as a positive control as reported previously ([@B80]; [@B53]).

![Melatonin ameliorated depressive-like behavior induced by LPS. **(A)** Locomotor activity analysis by open field test, **(B)** Sucrose preference test (SPT), **(C,D)** immobility analysis by tail suspension and FST. (*n* = 6 per group). Data are expressed as mean ± SEM, and results were analyzed using one-way ANOVA followed by *post-hoc* analysis. *p* \< 0.05 was considered statistically significant. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](fnmol-13-00096-g002){#F2}

Melatonin Modulated LPS-Induced Oxidative Stress and Altered AKT/GSK3β Signaling {#S3.SS2}
--------------------------------------------------------------------------------

An array of studies from experimental (*in vitro* and *in vivo*), as well as human studies, support the role of oxidative stress in the progression of diseases including neurological disorders ([@B36]; [@B24]). Moreover, altered redox-sensitive signaling including Akt/GSK3b accelerates free radical generation, followed by cytokines production, which can lead to neuroinflammation ([@B85]; [@B33]; [@B47]). Herein, our results indicated elevated serum ROS ([Figure 3A](#F3){ref-type="fig"}), hippocampus TBARs ([Figure 3B](#F3){ref-type="fig"}), and Akt/GSK3b phosphorylation ([Figures 4A,B](#F4){ref-type="fig"}) in the LPS-treated mice, which were significantly reversed by melatonin treatment. However, after luzindole treatment, the effects of melatonin were abolished ([Figures 4C,D](#F4){ref-type="fig"}), suggesting the anti-oxidative capacity of melatonin.

![Melatonin attenuated oxidative stress. **(A,B)** Column graphs representing the quantified ROS levels in serum and TBARs level in the hippocampal tissues of experimental mice. Data are expressed as mean ± SEM, and results were analyzed using one-way ANOVA followed by *post-hoc* analysis. *p* \< 0.05 was considered statistically significant. \**p* \< 0.05, \*\**p* \< 0.01.](fnmol-13-00096-g003){#F3}

![Melatonin decreased Akt and GSK3β phosphorylation induced by LPS. **(A)** Relative Phospho-Akt expression normalized by total Akt. **(B)** Represent Akt Phosphorylation in the hippocampus area of experimental animals normalized by total Akt. **(C,D)** Column graphs representing relative p-GSK3β expression in the hippocampus of animal models treated with LPS/drugs normalized by total GSK. Data are expressed as mean ± SEM, and results were analyzed using one-way ANOVA followed by *post-hoc* analysis. *p* \< 0.05 was considered statistically significant. \**p* \< 0.05, \*\**p* \< 0.01.](fnmol-13-00096-g004){#F4}

Melatonin Reduced Neuro-Inflammation Elicited by LPS {#S3.SS3}
----------------------------------------------------

LPS is a well-known inflammatory agent and it activates astrocytes and microglia followed by the pro-inflammatory cytokine-like TNF-α and IL-6, productions ([@B66]; [@B82]; [@B77]). Both serum and tissue ELISA results indicated that LPS-treatment significantly accelerated pro-inflammatory cytokines including IL-1β ([Figures 5A,C](#F5){ref-type="fig"}), IL-6 ([Figures 5E,G](#F5){ref-type="fig"}), and TNF-α ([Figures 5I,K](#F5){ref-type="fig"}) concentration while melatonin treatment reversed these changes.

![Melatonin attenuated LPS-induced Cytokines elevation. **(A,B)** IL-1β level in the hippocampus, **(C,D)** Serum IL-1β level, **(E,F)** IL-6 level in the hippocampus, **(G,H)** Serum IL-6 level, **(I,J)** TNFα level in the hippocampus, and **(K,L)** Serum TNFα level. Data are expressed as mean ± SEM, and results were analyzed using one-way ANOVA followed by *post hoc* analysis. *p* \< 0.05 was considered statistically significant. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](fnmol-13-00096-g005){#F5}

Moreover, numerous stimuli including cytokines, chemokines, LPS, and oxidative stress induce NF-κB activation, which subsequently plays a key role in the neuroinflammation by accelerating cytokines productions ([@B50]; [@B30]). Herein, our results showed markedly increased NF-κB phosphorylation ([Figure 6A](#F6){ref-type="fig"}) in the brain of LPS-treated mice, which was normalized after melatonin treatment. Furthermore, melatonin treatment attenuated LPS-mediated glial cells activation markers including GFAP and Iba-1 expression ([Figures 7A,B](#F7){ref-type="fig"}). However, after the melatonin receptor blocking by luzindole melatonin protective effect against LPS induced neuroinflammation was reduced ([Figures 5B,D,F,H,J,L](#F5){ref-type="fig"}, [6B](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"}), suggesting the key protective potential of melatonin against LPS induced neuroinflammation.

![Melatonin reduced LPS-induced NF-kB expression. **(A,B)** Represents immunoblots indicating the expression of *p*-NF-κB/NF-κB in the hippocampus of experimental mice. All the values are expressed as mean ± SEM: ANOVA followed by *post hoc* analysis. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](fnmol-13-00096-g006){#F6}

![Melatonin inhibited microglia and astrocyte activation by LPS. **(A)** Iba-1 positive microglia (green) and **(B)** GFAP-positive astrocytes (red). Column graphs representing the immunoreactive intensity of the microglia as well as astrocytes. *p* \< 0.05 was considered statistically significant. \**p* \< 0.05, \*\**p* \< 0.01.](fnmol-13-00096-g007){#F7}

Melatonin Regulates Nrf2/Sirt1/HO-1 Expression in the Hippocampus Area of Experimental Animals {#S3.SS4}
----------------------------------------------------------------------------------------------

Nrf2 is a well-known master regulator of redox homeostasis and cytoprotective protein involved in antioxidant reactions as well as inflammation ([@B13]; [@B43]) while Sirt 1 has been currently implicated in depression ([@B1]; [@B41]; [@B10]). In the present study, our results demonstrated that LPS-treatment had no significant effect on Nrf2 expression in the hippocampal area of the brain. However, increased Nrf2 expression was detected in the brain of the melatonin-treated mice ([Figures 8A,B](#F8){ref-type="fig"}). Similarly, melatonin-treatment enhanced Sirt1 expression in the brain of mice, which was suppressed by LPS treatment ([Figures 8A,C](#F8){ref-type="fig"}). Interestingly, luzindole treatment abolished these effects of melatonin on Nrf2 as well as Sirt1 expression ([Figures 8E--G](#F8){ref-type="fig"}).

![Melatonin elevated Nrf2, Sirt1, and HO-1 expression receptors dependently in the hippocampus area. **(A,E)** Representative blots show Nrf2, Sirt1, and HO-1 expression, **(B,F)** representing Nrf2 relative expression, and **(C,G)** shows Sirt1 expression in the hippocampus of the animal model. **(D,H)** Quantitative analysis of HO-1. Quantified results were normalized to GAPDH. All the values are expressed as mean ± SEM: ANOVA followed by *post hoc* analysis. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](fnmol-13-00096-g008){#F8}

Next, we measured HO-1 expression, a key anti-inflammatory agent regulated by Nrf2 ([@B40]). Elevated HO-1 expression was detected in the melatonin-treated mice hippocampus ([Figures 8A,D](#F8){ref-type="fig"}). However, this effect of melatonin was abolished after luzindole administration ([Figures 8E,H](#F8){ref-type="fig"}), suggesting melatonin receptor-dependent regulation of HO-1 expression.

Discussion {#S4}
==========

In the present study, we studied the neuroprotective effect of melatonin, against LPS-induced neuroinflammation and depressive-like behaviors. LPS treatment significantly induced depressive-like behaviors, oxidative stress, proinflammatory cytokines production, and NF-κB activation, followed by enhanced Iba-1 and GFAP expression in the hippocampus. However, the melatonin treatment attenuated depressive-like behaviors, oxidative stress, and neuroinflammation. Interestingly, luzindole treatment significantly abolished the effect of melatonin on depressive-like behaviors, oxidative stress as well as neuroinflammation. Moreover, melatonin mediated LPS effects on Sirt1/Nrf2/HO-1 signaling, which were abolished by luzindole treatment.

Lipopolysaccharide as cytokine inducer evoke peripheral and central immune activation in animal leading to neuroinflammation, accompanied by depressive-like behaviors ([@B71]; [@B53]; [@B93]). In agreement with the previous findings ([@B61]; [@B90]; [@B91]), our results demonstrated depressive-like behaviors upon LPS-treatment, which was reversed by melatonin treatment. Besides, LPS dysregulates PI3K/Akt/GSk3b signalings, which plays a crucial role in survival, proliferation, and invasion by generating the second messengers ([@B18]). Moreover, the PI3K-Akt/GSK3b pathway further regulates the induction and expression of inflammatory genes expression that contributes to the onset of depression. In our present study, decreased Akt/GSK3β phosphorylation was detected at 24 h post-LPS-treatment, which was significantly elevated by melatonin.

Growing evidence suggests that PI3K-Akt pathways regulate NF-κB expression and its downstream regulator ([@B14]; [@B26]; [@B35]; [@B47]). NF-κB plays an important role in the regulation of immunity and inflammation ([@B59]; [@B49]; [@B50]; [@B72]; [@B29]). Upon activation via upstream regulatory elements such as Toll-like receptor-4, NF-κB translocate to the nucleus as a transcription factor and regulates numerous inflammatory regulators including TNF-α expression. Furthermore, increased TNFα, IL-6, and IL-1β in the LPS treated mice suggest immune imbalance which was determined via pro and anti-inflammatory cytokines measurement. Besides the neuroinflammatory pathways, free radicals such as ROS play a key role in the neuroinflammation by regulating pro as well as anti-inflammatory signaling ([@B56]). Dysregulated redox-sensitive signalings contribute a significant role in an immune imbalance accompanied by depression ([@B24]; [@B86]). In the current study, our results showed that LPS significantly accelerated free radical generation, which was attenuated by melatonin treatment. Moreover, excessive free radicals such as ROS can induce NF-κB activation, followed by multiple inflammatory gene expression ([@B70]; [@B24]; [@B42]), supporting the hypothesis that neuroinflammation leads to depression. Consistent with the previous reports ([@B68]; [@B44]; [@B73]), our findings showed that a significant Sirt1 gene suppression in the LPS-treated mice brain, which was improved by melatonin treatment. However, melatonin effects were abolished by luzindole treatment. Previously, Sirt1 dependent Nrf2 expression has been reported, and after inhibition of Sirt1 via inhibitor, enhanced pro-inflammatory cytokines and as well as p-NF-κB expression were detected upon LPS administration, suggesting a sirt1 role in LPS induced neuroinflammation ([@B51]; [@B69]; [@B76]; [@B73]; [@B45]; [@B83]; [@B52]; [@B89]; [@B96]).

NF-κB regulates Nrf2 transcription and activity, whose downregulation/abrogation leads to increase NF-κB activity and enhanced cytokine production ([@B37]; [@B30]; [@B42]; [@B13]). Herein, melatonin treatment significantly increased Nrf2 and anti-inflammatory protein HO-1 expression which was down-regulated in the presence of melatonin receptor (MT1/MT2) inhibitor, suggesting the melatonin in a receptor-dependent manner regulates NF-κB/Nrf2/HO-1 expression ([@B66]; [@B62]; [@B16]). HO-1 contributes a significant role in modulating the inflammatory response. Many anti-inflammatory mediators have been demonstrated to enhance HO-1 expression, which subsequently inhibits inflammation ([@B38]; [@B39]). Recently it has been demonstrated that melatonin acts through the Nrf2 pathway and prevents the decline of antioxidant enzyme activities during brain pathological conditions ([@B54]; [@B51]; [@B22]; [@B96]), supporting our results that endogenous melatonin counterbalances the oxidative stress by boosting the body antioxidants system via its receptors. Our results are also in agreement with growing evidence that melatonin enhances HO-1 expression via NF-κB, p38 MAPK, and Nrf2 cascade signaling mechanism ([@B69]; [@B90]; [@B73]; [@B45]; [@B94]; [@B62]; [@B88]; [@B16]; [@B21]; [@B97]; [@B96]).

Conclusion {#S5}
==========

In conclusion, our study showed that LPS treatment stimulates pro-inflammatory cytokines production and induce oxidative stress imbalance followed by NF-κB activation, which leads to neuroinflammation along with depressive-like behaviors. Also, LPS-treatment significantly reduced Akt/GSK3b phosphorylation as well as Sirt1 expression. Melatonin acts as a neuroprotective agent abolished LPS effects on oxidative stress, NF-κB activation, redox-sensitive signaling, and depressive-like behaviors in a receptor-dependent manner. Further, these findings also proposed an indispensable relation of the antioxidative and anti-inflammatory activities of melatonin. Finally, the molecular changes underlying melatonin's effects may provide potential therapeutic candidates for the treatment of neuroinflammation associated depression.
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